Agriculture Biotechnology Market by Type of Organism (Plant, Animal, and Microbes), Type, Technology, Application, and Region - Global Forecast to 2030 The global agriculture biotechnology market was valued at USD 84.39 billion in 2024 and is projected to reach USD 144.25 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.4% during 2025–2030. Market growth is fueled by the rising adoption of genetically modified (GM) crops, microbial biofertilizers, animal vaccines, and sustainable biote ...

In Lambert High School's lab, Shaun Lee and his classmates are teenage genetic engineers manipulating the building blocks of life. >> And what we're going to do is we're going to move each of these samples into these mixes. And these mixes have everything we need in order to amplify our DNA.>> It's It's currently amplifying. >> Yes. All right.And we'll have to do this three more times for our different samples. So you would kind of swipe across. >> We went to check out the IGM team's project for the big Par ...

Genetically engineered babies are banned. Tech billionaires are trying to make one anyway. https://t.co/fLk4n5gt6v ...

Core Insights - Kraig Biocraft Laboratories, Inc. has significantly increased the production throughput of its recombinant spider silk production platform, marking a major advancement in spider silk technology [1][6]. Company Developments - The increase in production is attributed to the successful selective breeding of parental strains for hybrid silkworms, which form the basis of the recombinant spider silk production system [2][3]. - The first successful hybrid, BAM-1, demonstrated hybrid vigor, leading to increased cocoon shell weight and robustness, which are critical for silk output [2][4]. - The new advanced hybrid, BAM-1 Alpha, has shown a measurable hybrid vigor increase of 22%, representing over a 245% improvement compared to the original BAM-1 [4][5]. Production and Commercialization - The BAM-1 Alpha hybrid is expected to be the primary production strain moving forward, producing larger cocoons and more silk, which will lower production costs [5][6]. - Kraig Labs plans to leverage its multi-facility production infrastructure to integrate BAM-1 Alpha into ongoing manufacturing, supporting its vision of delivering high-performance spider silk fibers for various applications [6][7]. Industry Position - Kraig Labs continues to lead in spider silk research and development, focusing on large-scale commercialization of spider silk technologies [5][7]. - The company's advancements in spider silk technology have significant implications for the global textile industry, with potential applications in performance textiles, defense, medical, and industrial markets [6][10].

Core Insights - Kraig Biocraft Laboratories has achieved a significant milestone in biotechnology by successfully mass-producing spider silk using genetically engineered silkworms, addressing a long-standing challenge in the field [1][4][5] Company Overview - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) focuses on the development and commercialization of spider silk-based fiber technologies, utilizing a proprietary silkworm-based genetic engineering platform to produce high-performance, cost-effective, and scalable spider silk materials [8] Technological Breakthrough - The company’s genetically engineered silkworms serve as a factory for spider silk production, enabling a scalable and sustainable supply chain that transitions spider silk from laboratory research to practical applications [4][5] Market Potential - The global spider silk market is projected to grow significantly, with forecasts estimating it will reach between $1.3 billion and $1.5 billion by 2035, reflecting a compound annual growth rate (CAGR) of over 30% [6] - This growth is expected to be driven by demand in various sectors, including biomedical applications (sutures, scaffolds, implants), textiles, military uses, and sustainable materials for aerospace and automotive industries [6] Unique Properties of Spider Silk - Spider silk is recognized for its exceptional mechanical properties, including a superior tensile strength-to-weight ratio, outperforming materials like Kevlar and steel [6][7] - Its biocompatibility and biodegradability make it an attractive option for various applications, particularly in biomedical and sustainable material sectors [2][6] Applications and Opportunities - Potential applications for spider silk include stronger and lighter wearables, biodegradable sutures, next-generation body armor, sustainable textiles, and biomimetic actuators in robotics [9]

Core Technology & Scientific Advancements - The industry is at the cusp of programming life by understanding and manipulating cells like sophisticated software [5][6] - Systems biology offers a holistic approach to reprogramming life by mapping molecular interactions within cells, similar to a city-wide traffic map, to identify bottlenecks in disease networks [7][8] - Genetically Encoded Metabolic Manipulators and Sensors (GEMS) are DNA-based living therapies that act as molecular smoke detectors to restore balance in cancer cells [13] - Synthetic biology tools, like CRISPR, enable modular design of living therapies, allowing for rapid updates and adaptive defense strategies against diseases [14] Applications & Bioeconomy - Synthetic biology can be applied to create sustainable biofactories for producing fuels, food flavors, and materials from renewable resources, reducing reliance on fossil fuels and carbon emissions [19] - Microbial strains can be engineered to produce valuable compounds like violacein (a purple pigment with antimicrobial properties) and vanillin (vanilla flavor), as well as biodegradable plastics [20][21] - Synthetic biology is rewriting product design and rebuilding global supply chains, potentially impacting various industries from toothpaste to pharmaceuticals [23] Ethical Considerations & Future Implications - Advances in genetic engineering raise ethical questions about genetic personalization, designer babies, and the potential for exacerbating social inequalities [25] - The industry emphasizes the need for public awareness, open dialogue, and responsible governance to navigate the ethical implications of programming life [26] - The industry is at the dawn of a biological renaissance, with DNA as the code and humanity as the storytellers, holding the power to program life itself [28]

Biotechnology & Genetic Engineering - Genetic engineering is proposed to create miniature pet Wooly Mammoths [1] - The goal is to produce "adorable" miniature versions [1]

Company Overview - Colossal Biosciences is a genetic engineering company focused on de-extinction of species like the direwolf and woolly mammoth [2] - Colossal aims to undo past human actions that led to extinction [3] De-extinction Technology - De-extinction involves extracting DNA from ancient remains and editing genes of current relatives to create embryos or eggs of extinct animals [3] - Peter Jackson, director of Lord of the Rings, is partnering with Colossal and providing access to 300-400 Moa bones [4] Moa Bird Project - The Moa was a 13.5 ft (approximately 4.11 meters), 500 lb (approximately 226.8 kilograms) giant bird native to New Zealand, with nine known species [1] - Humanity hunted the Moa to extinction approximately 600 years ago [2] - The goal is to provide the resurrected Moa with a natural environment [4] Conservation and Ethical Considerations - Ecologists raise concerns about potential risks associated with de-extinction technologies and the release of resurrected species into the environment [5] - Colossal believes bringing back extinct species can highlight the biodiversity crisis [5]

Investment Rating - The report indicates a strong investment interest in the plant biotech sector, with a notable increase in venture capital funding and a focus on early-stage deals, despite a broader downturn in agtech funding [4][8]. Core Insights - Plant biotech startups attracted $1.2 billion in VC funding in 2024, marking a 78.3% year-over-year increase, demonstrating sector resilience [4]. - Gene-editing technologies like CRISPR have democratized seed development, allowing startups to innovate rapidly without the high costs associated with traditional GMO standards [4][10]. - The rising costs of fertilizers and pesticides are driving the adoption of biological inputs, with AI technology expected to enhance target identification and reduce development costs [4][8]. - Successful exits for agricultural biotech startups have been rare, making the next few years critical for establishing success in the plant biotech space [4]. Overview - Advances in biotechnology over the past 20 years have transformed agriculture, with genetic engineering becoming standard and biological inputs emerging as sustainable alternatives to traditional agrochemicals [7]. - The VC ecosystem has significantly contributed to the growth of plant biotech startups, with cutting-edge technologies enabling rapid innovation in agricultural sustainability and productivity [8]. Opportunities - AI and machine learning applications are revolutionizing the identification of gene targets and beneficial microbial interactions, streamlining the development of new crop varieties and biological products [36]. - Gene editing is facilitating the development of new traits at unprecedented speed and precision, with several startups approaching commercialization of innovative crop varieties [37]. Technologies and Processes - The report categorizes various segments within plant biotech, including genetic improvement, plant data and diagnostics, bionutrients, and biocontrol solutions, highlighting key startups in each area [28][30][33]. - Startups are leveraging advanced genetic technologies and bioinformatics to enhance crop traits, assess plant health, and develop sustainable agricultural practices [29][30][31]. Recent Deal Activity and Market Outlook - Despite a decline in overall agtech VC deal activity, plant biotech saw a significant increase in deal value, attributed to large rounds for maturing biotech companies and sustained interest in early-stage deals [47]. - The report notes that while VC funding for plant biotech startups is substantial, successful exits remain uncommon, with a few notable IPOs in related sectors [48].